In the field of hematological malignancies, Blinatumomab is a Bi-specific T Cell Engager (BiTE) that simultaneously targets CD19 antigen on the Acute Lymphoblastic Leukemia (ALL) and CD3 on T- cells [6, 7] to induce efficient killing of leukemia cells (FDA approval in 2014). This evidence concerns the gene CACNA1A and acute lymphoblastic leukemia.